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Abstract
Objective: Multivitamin supplements are used by nearly half of middle-aged
women in the USA. Despite this high prevalence of multivitamin use, little is
known about the effects of multivitamins on health outcomes, including cancer
risk. Our main objective was to determine the association between multivitamin
use and the risk of breast cancer in women.
Design: We conducted a population-based case–control study among 2968 inci-
dent breast cancer cases (aged 20–69 years), diagnosed between 2004 and 2007,
and 2982 control women from Wisconsin, USA. All participants completed a
structured telephone interview which ascertained supplement use prior to diag-
nosis, demographics and risk factor information. Odds ratios and 95 % confidence
intervals were calculated using multivariable logistic regression.
Results: Compared with never users of multivitamins, the OR for breast cancer was
1?02 (95 % CI 0?87, 1?19) for current users and 0?99 (95 % CI 0?74, 1?33) for former
users. Further, neither duration of use (for $10 years: OR5 1?13, 95 % CI 0?93,
1?38, P for trend5 0?25) nor frequency (.7 times/week: OR5 1?00, 95 % CI 0?77,
1?28, P for trend5 0?97) was related to risk in current users. Stratification by
menopausal status, family history of breast cancer, age, alcohol, tumour staging
and postmenopausal hormone use did not significantly modify the association
between multivitamin use and breast cancer.
Conclusions: The current study found no association between multivitamin
supplement use and breast cancer risk in women.
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All types of dietary supplements are becoming increasingly
common in the USA and the prevalence of use is highest in
adult women, with 38% reporting multivitamin use(1,2). This
increasing trend in the use of dietary supplements may have
an impact on health in the population(3). Commonly, indi-
viduals use multivitamin supplements for general health
promotion or to make an existing disease less severe.
However, assessing the role of dietary supplements on
the intake of vitamins and minerals is complicated by the
fact that the USA has been fortifying food with specific
micronutrients, starting in 1924 with iodized salt. Since
then the USA has added vitamin D in milk, B-vitamins in
flour and bread, and folate in cereal grain-based foods,
for public health reasons(4). The level and variety of food
fortification in the USA has increased over time(4,5) and, in
combination with dietary supplements, might lead to a
daily intake of certain nutrients above the Upper Tolerable
Intake Level (UL)(6).
The use of dietary supplements may adversely impact
health due to excessive intake of certain micronutrients(7).
At the same time, dietary supplements have been asso-
ciated with meeting the Recommended Daily Allowances
(RDA) and Adequate Intakes (AI) for certain micro-
nutrients in the US population(7). Therefore, the role that
supplementation for these micronutrients plays in pro-
moting health and preventing disease is unclear(6). Such
intake may be particularly relevant in carcinogenesis.
For example, many multivitamin supplements include
folate (or folic acid). Additional folate may provide pro-
tection early in carcinogenesis, especially in individuals
with a low folate status(8). On the other hand, folate may
promote carcinogenesis if precancerous lesions or
malignant cells are already present in an individual or if
folate intake is particularly high(9). Therefore, the role and
optimal intake of folate for cancer prevention remain
uncertain(10).
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Several observational studies have specifically assessed
the influence of multivitamin use on breast cancer risk
and showed contradictory results. Some studies report a
19–33 % increased risk of breast cancer associated with
multivitamin use(11,12), while others show a reduced risk
of 20–43 %(13–15) or find no association(16–19).
Due to the high intake of supplemental vitamins and
minerals in the USA and the potential carcinogenic role of
excessive micronutrient intake, it is important to evaluate
the role of multivitamins in cancer risk. In the present
study, we investigated the association between multi-
vitamin supplement use and breast cancer risk by con-
ducting a population-based case–control study among
women in Wisconsin, USA.
Subjects and methods
Ethics
The protocols for, and conduct of, the study were
approved by the University of Wisconsin Institutional
Review Board.
Selection of cases
Cases were identified via the Wisconsin Cancer Reporting
System, a state-wide registry that covers all cases of
cancer among residents of Wisconsin. This registry uses
hospital, physician and clinic reports to identify cancer
cases. All cases must be reported to the registry within
6 months of diagnosis. For these analyses, we restricted
cancer cases to women living in Wisconsin, aged 20–69
years, diagnosed with a first invasive breast cancer
between 2004 and 2007. Eligible cases had a published
telephone number, reported dates of diagnosis and dri-
ver’s license verified by self-report. Of the 4021 eligible
cases, eighty-four (2?1 %) were deceased, 198 (4?9 %)
could not be located and 747 (18?6 %) refused to parti-
cipate. A total of 2992 were interviewed (74 % response
rate). Data for four interviewed cases were considered
unreliable by the interviewers. After removing twenty
(0?7 %) cases for missing values of multivitamin use, 2968
cases were eligible for the analysis.
Selection of controls
Community controls were selected at random (within
5-year age strata similar to cases) from lists of licensed
drivers from the Wisconsin Department of Transportation.
Inclusion criteria required a publicly available telephone
number and no personal history of breast cancer. We
identified 4500 eligible women, but were not able to
interview all women due to inability to locate 327 (7?3 %),
refusal of 1152 (25?6 %) or death of sixteen (0?4 %). A total
of 3005 were interviewed, and overall response rate was
67 %. Data for one interviewed control were considered
unreliable by the interviewer and twenty-two (0?7 %)
controls were removed from analysis for missing values of
multivitamin supplement use, leaving 2982 controls eligi-
ble for analysis.
Exposure assessment
Study participants were sent letters briefly describing the
study before they were contacted via telephone by trained
interviewers. These interviewers explained the study,
answered participants’ questions, and obtained oral consent
for study participation prior to the interview. Case subjects
and controls then completed a structured 30min telephone
interview eliciting information on known or suspected risk
factors for breast cancer. Participants were asked if they had
ever taken a multivitamin supplement for at least three
consecutive months in the year prior to the reference data.
Furthermore, participants were asked the year they started
and stopped taking supplements, how long they took
multivitamins, and how many multivitamins they took each
day. Moreover, information about menstrual and repro-
ductive history, menopausal status, family and personal
medical history, education, smoking status, physical activity,
height, weight and demographics was collected.
Clinical information about tumour staging and first
course of treatment was obtained from the Wisconsin
Cancer Reporting System.
Statistical analysis
A reference date for cases was defined as the registry-
supplied date of invasive breast cancer diagnosis. Controls
were assigned an individual reference date so that their
exposure assessment time frame was similar to that of
cases. Only multivitamin use prior to the reference date
was included in the analysis.
Participants were classified as never, former or current
multivitamin users. The reference category, non-users,
included only individuals who had never taken multivitamin
supplements for at least 3 months. ‘Former’ use was defined
as taking multivitamin supplements for 3 months or more at
any time prior to the reference date, but not taking sup-
plements at the time of the reference date; ‘current’ use was
defined as taking multivitamin supplements for at least 3
months at the time of the reference date. Among former
users, duration of use was categorized as ,5 years and $5
years. Among current users, duration of use was ,5 years,
5–9 years and $10 years. The frequency of use (i.e. the
number of multivitamins consumed each week) among
current users was categorized as #7 multivitamins/week
and.7 multivitamins/week. A continuous variable, years of
use, was also evaluated.
The association between multivitamin supplement use
and the risk of breast cancer was determined by calcu-
lating odds ratios and 95 % confidence intervals using
multiple logistic regression models. The odds ratios were
estimated according to categories of multivitamin sup-
plement use and adjusted for reference age. In addition,
we performed a logistic regression that adjusted for
potential confounders, including age at reference date
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(in 5-year categories), education (less than high school, high
school graduate, some college, college graduate), BMI
(,18?5, 18?5–24?9, 25?0–29?9, $30?0kg/m2), alcohol (none,
1–7, .7 drinks/week), breast biopsy (never, ever), family
history of breast cancer in a mother or sister, age at
menarche (,12, 12–14, .14 years), parity (0, 1–2, $3), age
at first birth (,20, 20–30,.30 years), menopausal status, age
at menopause and postmenopausal hormone use (among
postmenopausal women only). Tests of trend were eval-
uated by conducting separate logistic regression analyses
replacing the categorical variable for duration and frequency
of multivitamin use with the ordinal variables for these terms
and examining the Wald P value for the ordinal terms. Since
previous reports have demonstrated that age, alcohol, family
history of breast cancer, menopausal status and post-
menopausal hormone use are important risk factors for
breast cancer(20), effect modification was assessed through
stratified analyses and evaluated by adding cross-product
interaction terms to the multivariate model. All P values were
two-sided and statistical significance was evaluated at 0?05.
The data were analysed using the SAS statistical software
package version 9?1 (SAS Institute, Cary, NC, USA).
Results
Use of multivitamin supplements was common among
women in the present study; approximately 50 % of cases
and controls were current users of multivitamins and
8–9 % former multivitamin users.
Cases had an earlier age of menarche and fewer preg-
nancies than controls (Table 1). Furthermore, cases tended
to have higher education, higher levels of alcohol intake, a
previous breast biopsy, a family history of breast cancer, a
later age at first birth and a later age at menopause.
In the multivariable adjusted models, multivitamin use
was not associated with the risk of breast cancer (Table 2).
The adjusted OR was 0?99 (95% CI 0?74, 1?33) for former
use and 1?02 (95% CI 0?87, 1?19) for current use of multi-
vitamin supplements. Furthermore, no significant associa-
tion with breast cancer risk was observed for duration of
multivitamin use, regardless of whether women were cur-
rent or former users. These data suggested that current users
who took multivitamins for at least 10 years had a modest
increased risk compared with never users (OR51?13, 95%
CI 0?93, 1?38), but this was not statistically significant and
did not reflect a dose–response (P for trend50?25). In
addition, frequency of use was not associated with intake;
women who took multivitamins .7 times/week had an OR
of 1?00 (95% CI 0?77, 1?28) compared with never users of
multivitamins (P for trend50?97).
The association between breast cancer and multi-
vitamin use stratified by menopausal status is presented in
Table 3. Among premenopausal women, the adjusted
OR was 0?87 (95 % CI 0?62, 1?23) for former users
and 0?87 (95 % CI 0?70, 1?08) for current users. Among
postmenopausal women, the OR was 0?99 (95 % CI 0?74,
1?33) for former users and 1?03 (95 % CI 0?88, 1?20) for
current users. There was no significant interaction
between multivitamin use and postmenopausal hormone
use (P5 0?82). In addition, age, alcohol use, family his-
tory of breast cancer or tumour stage did not significantly
modify the association between multivitamin use and
breast cancer (P for interaction .0?05; data not shown).
Discussion
Our findings indicate that there is no association between
use of multivitamin supplements and breast cancer risk in
Table 1 Baseline characteristics among breast cancer cases and
controls, Wisconsin, USA, 2002–7
Cases Controls
Characteristic n %* n %*
Age (years)
20–40 184 6?2 167 5?6
40–49 787 26?5 743 24?9
50–59 1075 36?2 1080 36?2
60–69 922 31?1 992 33?3
Education
Less than high school 79 3?0 108 4?0
High school graduate 1130 42?7 1125 41?7
Some college 782 29?5 880 32?6
College graduate 639 24?1 566 21?0
BMI (kg/m2)
,18?5 41 1?4 36 1?2
18?5–24?9 1224 41?8 1184 30?0
25?0–29?9 870 29?7 882 40?3
$30?0 759 25?9 797 27?1
Alcohol consumption (drinks/week)
None 577 19?4 641 21?5
1–7 2109 71?1 2068 69?4
.7 277 9?3 264 8?9
Breast biopsy
Never 2120 71?4 2331 78?2
Ever 805 27?1 605 20?3
Positive family history of breast cancer
No 2314 78?0 2489 83?5
Yes 591 19?9 427 14?3
Age at menarche (years)
,12 609 21?1 530 18?3
12–14 1927 66?8 1980 68?3
.14 343 11?9 384 13?3
Parity
0 425 14?3 370 12?4
1–2 1440 48?5 1317 44?2
$3 1088 36?7 1289 43?2
Age at first birth (years)-
,20 431 14?5 509 17?1
20–30 1687 56?8 1800 60?4
.30 387 13?0 285 9?6
Menopausal status
Premenopausal 989 33?3 918 30?8
Postmenopausal 1664 56?1 1797 60?3
Age at menopause (years)-
-
,45 207 12?4 317 17?7
45–54 821 49?3 825 46?0
.54 258 15?5 258 14?4
*Due to missing values, some categories do not sum to 100 %.
-Among parous women only.
-
-
Among postmenopausal women only.
1542 JM Meulepas et al.
this population. Neither current users who used multi-
vitamins for long durations, nor those who took more
than one multivitamin per day, had a significantly differ-
ent risk of breast cancer than those who never took
multivitamins. Moreover, menopausal status, family history
of breast cancer, postmenopausal hormone use, tumour
stage, alcohol use or age did not modify the association
between multivitamin use and breast cancer risk.
Several previous studies examined the relationship
between multivitamin supplement use and the risk of
Table 2 Odds ratios and 95 % confidence intervals for the risk of breast cancer according to use of multivitamin supplements among
women in Wisconsin, USA, 2002–7
Multivitamin use Cases/controls OR* 95 % CI Multivariable OR- 95 % CI
Status
Never use 1216/1213 1?00 ref 1?00 ref
Former use 247/276 0?88 0?72, 1?06 0?99 0?74, 1?33
Current use 1505/1493 1?01 0?91, 1?12 1?02 0?87, 1?19
Duration (years)
Never use 1216/1213 1?00 ref 1?00 ref
Former use
,5 161/179 0?88 0?70, 1?10 0?90 0?62, 1?30
$5 86/97 0?88 0?65, 1?19 1?14 0?73, 1?78
P for trend 0?92 0?89
Current use
,5 471/462 1?02 0?87, 1?18 1?09 0?87, 1?35
5–9 338/399 0?85 0?72, 1?00 0?82 0?65, 1?03
$10 696/632 1?10 0?97, 1?26 1?13 0?93, 1?38
P for trend 0?15 0?25
Frequency (no. of times/week)-
-
Never use 1216/1213 1?00 ref 1?00 ref
#7 1170/1182 0?99 0?89, 1?11 1?02 0?87, 1?20
.7 335/311 1?08 0?90, 1?28 1?00 0?77, 1?28
P for trend 0?41 0?97
ref, referent category.
*Models were adjusted for reference age.
-Multivariable models were adjusted for reference age, education, BMI, alcohol consumption, biopsy, family history of breast cancer, age at menarche, parity,
age at first birth, menopausal status, postmenopausal hormone use (among postmenopausal women only) and age at menopause (among postmenopausal
women only).
-
-
Analysis among current users and never users.
Table 3 Odds ratios and 95 % confidence intervals for the risk of breast cancer according to use of multivitamin supplements among
women stratified by menopausal status, Wisconsin, USA, 2002–7
Premenopausal Postmenopausal
Multivitamin use Cases/controls Multivariable OR* 95 % CI Cases/controls Multivariable OR* 95 % CI
Status
Never use 417/373 1?00 ref 675/741 1?00 ref
Former use 103/113 0?87 0?62, 1?23 116/135 0?99 0?74, 1?33
Current use 469/432 0?87 0?70, 1?08 873/921 1?03 0?88, 1?20
Duration (years)
Never use 417/373 1?00 ref 67/741 1?00 ref
Former use
,5 73/75 0?93 0?63, 1?39 69/83 0?90 0?62, 1?30
$5 30/38 0?75 0?42, 1?34 47/52 1?14 0?73, 1?78
P for trend 0?50 0?93
Current use
,5 146/159 0?75 0?56, 1?01 270/268 1?09 0?87, 1?35
5–9 104/106 0?80 0?56, 1?13 201/259 0?82 0?65, 1?03
$10 219/167 1?02 0?78, 1?34 402/394 1?13 0?93, 1?38
P for trend 0?85 0?25
Frequency (no. of times/week)-
Never use 417/373 1?00 ref 675/741 1?00 ref
#7 356/334 0?87 0?69, 1?10 690/736 1?02 0?87, 1?20
.7 113/98 0?93 0?66, 1?30 183/185 1?00 0?77, 1?28
P for trend 0?65 0?97
ref, referent category.
*Multivariable models were adjusted for reference age, education, BMI, alcohol consumption, biopsy, family history of breast cancer, age at menarche, parity,
age at first birth, menopausal status, postmenopausal hormone use (among postmenopausal women only) and age at menopause (among postmenopausal
women only).
-Analysis among current users and never users.
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breast cancer. Two case–control studies found no associa-
tion(18,19). One of these studies, by Moorman et al.(19), was a
population-based case–control study in North Carolina
similar to our study except that it had a higher proportion of
African-American participants. The other was a population-
based case–control study in Shanghai(18). Furthermore, the
Nurses’ Health study(16), a prospective cohort study, repor-
ted null results for multivitamin supplements and breast
cancer risk. The researchers classified participants as
never, former and current multivitamin users and pre-
sented duration for current users as we did in our study.
Two observational studies demonstrated inverse asso-
ciations between breast cancer risk and multivitamins.
The Women’s Health Study(15) observed a non-significant
inverse association between the risk of oestrogen-recep-
tor-negative breast cancer and past multivitamin use
(OR5 0?60, 95 % CI 0?42, 1?06). In our study, tumour
hormone receptor status was not available. Furthermore,
the Nurses’ Health Study(14) presented an inverse asso-
ciation (relative risk5 0?57, 95 % CI 0?33, 0?98), but the
cases were restricted to sixty-seven women diagnosed
with atypical hyperplasia.
A case–control study in Denmark reported an increased
risk of breast cancer associated with multivitamin use
(OR5 1?33, 95% CI 1?09, 1?62)(11). That case–control study
included information on all dietary factors. Furthermore,
the study was conducted in a European population where
the composition of the multivitamins and the level of food
fortification may differ from those in the USA. Moreover,
the Danish study population had a lower percentage of
multivitamin users (26%) compared with our study
population which might have attenuated our results. For
example, if only a very low folate status increases the risk
of breast cancer, then strong associations can be detected
only in study populations that include a sufficient number
of subjects in the low-folate range(10).
The participants of our study had a higher percentage
(50%) of having ever used multivitamins compared with the
general population (38%)(2). However, our study popula-
tion was predominantly white women and had an older age
distribution than the general population. Compared with a
different survey where the authors stratified for race and
age, 47% of white adults used multivitamin supplements(21).
Therefore, our results may not be generalizable to popula-
tions with higher proportions of minorities.
Women with breast cancer may be more likely to begin
using multivitamin supplements after diagnosis. To limit
this potential bias, participants were asked about the use
of multivitamin supplements in the year prior to the
reference date.
The constituents of a multivitamin tablet vary by brand
and may be equal to or exceed the RDA for a particular
nutrient(22). Therefore, the supplement in conjunction
with nutrients from food intake could exceed the UL for
important nutrients. On average, one multivitamin tablet
is a major source of folate and vitamin B6, and has levels
of these vitamins that are equivalent to, or greater than, the
daily RDA for adults in the USA(23). In addition, the biolo-
gical effects of a nutrient are heavily dependent on its
absorption, transport, function and metabolism, all of which
can be affected by the presence of other nutrients(12). Thus,
the evaluations of dietary supplements are complex.
Some limitations should be considered in interpreting
our results. Information about total energy intake was not
available in our study. Therefore, we could not adjust for
the possible confounding effect of total energy intake.
However, we did adjust for BMI, which is a strong risk
factor for breast cancer and associated with total energy
intake(20). Also, we did not collect the exact supplement
composition in our study, and other studies have found
that estimating the exact intake of each micronutrient
from dietary supplements is important to evaluating out-
comes in epidemiological studies(24). We did however
obtain information about the frequency and duration of
multivitamin use for an examination of possible dose
effects. Furthermore, the goal of the present study was
not to examine individual components of multivitamins,
but rather to evaluate an extremely common risk factor,
multivitamin intake, in relation to breast cancer risk.
Finally, selection bias, recall bias and confounding may
have influenced the results of our study. Selection bias
may be present because of restriction criteria (driver’s
license and telephone number) for eligible women. This
may lead to the inclusion of women who tend to be better
educated than the general population and be partially
responsible for the higher percentage of supplement
users in our study population, because supplement use is
positively associated with education(1). In general,
women report the use of medications, including supple-
ments, with a high degree of validity so that recall bias is
probably limited(25). Also, confounding was unlikely to
have introduced substantial bias because we were able to
adjust for multiple potential confounders. Furthermore,
we did not recruit cases on the date of their diagnosis,
and therefore bias could be introduced into our study if
multivitamin use is associated with aggressive breast
cancers that are rapidly fatal. This is less of a concern with
breast cancer than it is with other types of cancer, because
greater than 90 % of breast cancer cases survive at least
five years. Even so, we attempted to limit this possible
bias by enrolling cases as soon as possible after diagnosis.
The majority of cases were enrolled within 2 years of
diagnosis.
The present study has several strengths. It is a popu-
lation-based study including a large sample size and
good response rates. We were able to evaluate both the
frequency and duration of multivitamin supplements by
making use of a standardized instrument.
In conclusion, the present study did not find an asso-
ciation between multivitamin use and breast cancer risk.
While dietary factors may be an important determinant
of cancer risk(26), the role of vitamin supplementation on
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breast cancer risk is still unclear. Understanding the risks
and benefits of dietary supplements is especially impor-
tant in the USA and other Western countries, where
dietary supplement use is high and the food supply is
already fortified with vitamins. Future studies evaluating
the relationship between specific micronutrients and
breast cancer risk should attempt to characterize the
composition of dietary supplements along with the intake
of specific nutrients from the diet.
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